In 2012, India’s patent department authorized a local drug maker to produce a generic version of the cancer drug Nexavar, claiming the drug’s creator, the German pharmaceutical Bayer, priced the drug out of reach for most Indians. Bloomberg recently reported that when Marijn Dekkers, Bayer’s CEO, spoke at a pharmaceutical forum last month, he was still angered by India’s decision. When referencing the Nexavar issue, Dekker said, “We did not develop this product for the Indian market, let’s be honest. We developed this product for Western patients who can afford this product.” He went on to say that India’s decision was essentially “theft”. Rohit Malpani, director of policy and advocacy for Doctors Without Borders joins us to discuss cost and access to pharmaceutical drugs in the developing world. (Photo: AP/Mahesh Kumar A., File)